Hardman & Co Research / GB00BYV81293
15.11.2023 - 08:30:02Hardman & Co Research on Shield Therapeutics (STX): Accelerating effectiveness of enlarged sales team
| Hardman & Co Research Hardman & Co Research on Shield Therapeutics (STX): Accelerating effectiveness of enlarged sales team 15-Nov-2023 / 07:30 GMT/BST The issuer is solely responsible for the content of this announcement. Hardman & Co Research on Shield Therapeutics (STX): Accelerating effectiveness of enlarged sales team Shield is a commercial-stage pharma company delivering specialty products that address patients’ unmet medical needs, with an initial focus on iron deficiency (ID). Since its US launch in July 2021, Shield has been increasing physician awareness of the differentiating characteristics of Accrufer® as an oral ID drug, with the aim of ramping up prescription (Rx) growth and sales traction. Positive Rx momentum in 2022 started to accelerate at the end of 1Q’23 and has continued into 3Q’23, following expansion of the Shield-Viatris commercial team. In the event that the US goals are achieved, there would be considerable upside potential to the valuation. Please click on the link below for the full report: https://hardmanandco.com/research/corporate-research/stx-accelerating-effectiveness-of-enlarged-sales-team/ If you are interested in meeting the company, you can register your interest by clicking on the above link
Dissemination of a CORPORATE NEWS, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. |
